Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

BI-3406, a Potent and Selective SOS1–KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition
Marco H. Hofmann, Michael Gmachl, Jürgen Ramharter, et al.
Cancer Discovery (2020) Vol. 11, Iss. 1, pp. 142-157
Open Access | Times Cited: 329

Showing 1-25 of 329 citing articles:

Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment
Laura D. Wood, Marcia I. Canto, Elizabeth M. Jaffee, et al.
Gastroenterology (2022) Vol. 163, Iss. 2, pp. 386-402.e1
Open Access | Times Cited: 481
The current state of the art and future trends in RAS-targeted cancer therapies
Salman R. Punekar, Vamsidhar Velcheti, Benjamin G. Neel, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 10, pp. 637-655
Open Access | Times Cited: 302
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
Gongmin Zhu, Lijiao Pei, Hongwei Xia, et al.
Molecular Cancer (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 281
Pan-KRAS inhibitor disables oncogenic signalling and tumour growth
Dong-Sung Kim, Lorenz Herdeis, Dorothea Rudolph, et al.
Nature (2023) Vol. 619, Iss. 7968, pp. 160-166
Open Access | Times Cited: 258
Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches
Martin Reck, David P. Carbone, Marina Chiara Garassino, et al.
Annals of Oncology (2021) Vol. 32, Iss. 9, pp. 1101-1110
Open Access | Times Cited: 219
Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants
Marco H. Hofmann, Daniel Gerlach, Sandra Misale, et al.
Cancer Discovery (2022) Vol. 12, Iss. 4, pp. 924-937
Open Access | Times Cited: 196
Translational advances in pancreatic ductal adenocarcinoma therapy
Abdel Hosein, Stephanie K. Dougan, Andrew J. Aguirre, et al.
Nature Cancer (2022) Vol. 3, Iss. 3, pp. 272-286
Open Access | Times Cited: 175
KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments
T. Koga, Kenichi Suda, Toshio Fujino, et al.
Journal of Thoracic Oncology (2021) Vol. 16, Iss. 8, pp. 1321-1332
Open Access | Times Cited: 172
Emerging strategies to target RAS signaling in human cancer therapy
Kun Chen, Yalei Zhang, Ling Qian, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 160
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Yue Zhou, Lei Tao, Jiahao Qiu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 134
The KRAS-G12C inhibitor: activity and resistance
Jiao Liu, Rui Kang, Daolin Tang
Cancer Gene Therapy (2021) Vol. 29, Iss. 7, pp. 875-878
Open Access | Times Cited: 130
Targeting KRAS mutant cancers: from druggable therapy to drug resistance
Chunxiao Zhu, Xiaoqing Guan, Xinuo Zhang, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 128
Therapeutic developments in pancreatic cancer
Zilun Hu, Eileen M. O’Reilly
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 21, Iss. 1, pp. 7-24
Closed Access | Times Cited: 128
Progress on Ras/MAPK Signaling Research and Targeting in Blood and Solid Cancers
Martha Dillon, Antonio R. Lopez, Edward H. Lin, et al.
Cancers (2021) Vol. 13, Iss. 20, pp. 5059-5059
Open Access | Times Cited: 106
Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications
Miguel A. Martín-Serrano, Benjamin Kepecs, Miguel Torres‐Martín, et al.
Gut (2022) Vol. 72, Iss. 4, pp. 736-748
Open Access | Times Cited: 90
Drugging KRAS: current perspectives and state-of-art review
Kaushal Parikh, Giuseppe Luigi Banna, Stephen V. Liu, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 83
Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors
Jessica Lee, Smruthy Sivakumar, Alexa B. Schrock, et al.
npj Precision Oncology (2022) Vol. 6, Iss. 1
Open Access | Times Cited: 73
Targeting KRAS in cancer
Anupriya Singhal, Bob T. Li, Eileen M. O’Reilly
Nature Medicine (2024) Vol. 30, Iss. 4, pp. 969-983
Closed Access | Times Cited: 71
Annual review of PROTAC degraders as anticancer agents in 2022
Xiao Wang, Zhao-Long Qin, Na Li, et al.
European Journal of Medicinal Chemistry (2024) Vol. 267, pp. 116166-116166
Closed Access | Times Cited: 53
New clinical trial design in precision medicine: discovery, development and direction
Xiao-Peng Duan, Bao‐Dong Qin, Xiao‐Dong Jiao, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 48
Exploiting the therapeutic implications of KRAS inhibition on tumor immunity
Mı́riam Molina-Arcas, Julian Downward
Cancer Cell (2024) Vol. 42, Iss. 3, pp. 338-357
Open Access | Times Cited: 46
Combinatorial strategies to target RAS-driven cancers
Naiara Perurena, Lisa Situ, Karen Cichowski
Nature reviews. Cancer (2024) Vol. 24, Iss. 5, pp. 316-337
Closed Access | Times Cited: 26
Characteristic roadmap of linker governs the rational design of PROTACs
Yawen Dong, Tingting Ma, Ting Xu, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 10, pp. 4266-4295
Open Access | Times Cited: 22
Targeting KRAS in pancreatic cancer
Sandra Stickler, Barbara H. Rath, Gerhard Hamilton
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics (2024) Vol. 32, Iss. 5, pp. 799-805
Open Access | Times Cited: 18
KRAS G12C inhibitor combination therapies: current evidence and challenge
Hirotaka Miyashita, Shumei Kato, David S. Hong
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top